C
CNS Pharmaceuticals, Inc. (CNSP)
NCM – Real Time Price. Currency in USD
6.12
-0.64 (-9.47%)
At close: May 12, 2026, 4:00 PM EDT
6.18
+0.06 (1.00%)
After-hours: May 12, 2026, 7:44 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.12
-0.64 (-9.47%)
At close: May 12, 2026, 4:00 PM EDT
6.18
+0.06 (1.00%)
After-hours: May 12, 2026, 7:44 PM EDT
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company’s drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
| Name | Position |
|---|---|
| Dr. E. Lynne Kelley F.A.C.S., M.D. | Chief Medical Officer |
| Mr. Christopher S. Downs C.P.A., CTP, FP&A | Senior Vice President of Finance |
| Mr. Dylan Wenke M.B.A. | Chief Business Officer |
| Mr. Eric Faulkner M.B.A., M.Sc. | Chief Technology Officer |
| Mr. Rami Levin M.B.A. | President, CEO & Director |
| Mr. Steve O'Loughlin M.B.A. | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-04 | 8-K | cns_8k.htm |
| 2026-04-30 | 10-K/A | cns_i10ka1-123125.htm |
| 2026-03-31 | 10-K | cns_i10k-123125.htm |
| 2026-03-11 | 8-K | cns_8k.htm |
| 2026-03-02 | 8-K | cns_8k.htm |
| 2026-02-27 | S-8 | cns_s8.htm |
| 2026-02-17 | 8-K | cns_8k.htm |
| 2025-12-17 | 8-K | cns_8k.htm |
| 2025-11-21 | 8-K | cns_8k.htm |
| 2025-11-14 | 10-Q | cns_i10q-093025.htm |